152 related articles for article (PubMed ID: 10335459)
1. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
[TBL] [Abstract][Full Text] [Related]
2. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
3. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
Mlakar DN; Bric TK; Škrjanec AL; Krajc M
Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
[TBL] [Abstract][Full Text] [Related]
4. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
[TBL] [Abstract][Full Text] [Related]
5. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
[TBL] [Abstract][Full Text] [Related]
6. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
[TBL] [Abstract][Full Text] [Related]
7. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.
Zorzi M; Hassan C; Senore C; Capodaglio G; Turrin A; Narne E; Mussato A; Rizzato S; Chinellato E; Zamberlan S; Repici A; Rugge M
J Med Screen; 2021 Jun; 28(2):131-139. PubMed ID: 32393153
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
Castiglione G; Visioli CB; Ciatto S; Grazzini G; Bonanomi AG; Rubeca T; Mantellini P; Zappa M
Br J Cancer; 2007 Jun; 96(11):1750-4. PubMed ID: 17453007
[TBL] [Abstract][Full Text] [Related]
9. Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.
Giorgi Rossi P; Carretta E; Mangone L; Baracco S; Serraino D; Zorzi M;
J Med Screen; 2018 Mar; 25(1):32-39. PubMed ID: 28195508
[TBL] [Abstract][Full Text] [Related]
10. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
11. Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.
Tam TK; Ng KK; Lau CM; Lai TC; Lai WY; Tsang LC
Hong Kong Med J; 2011 Oct; 17(5):350-7. PubMed ID: 21979470
[TBL] [Abstract][Full Text] [Related]
12. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
13. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
[TBL] [Abstract][Full Text] [Related]
14. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study.
Nakama H; Kamijo N; Abdul Fattah AS; Zhang B
J Med Screen; 1996; 3(2):63-5. PubMed ID: 8849761
[TBL] [Abstract][Full Text] [Related]
15. Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study.
Nakajima M; Saito H; Soma Y; Sobue T; Tanaka M; Munakata A
Br J Cancer; 2003 Jul; 89(1):23-8. PubMed ID: 12838295
[TBL] [Abstract][Full Text] [Related]
16. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
17. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
[TBL] [Abstract][Full Text] [Related]
18. Faecal occult blood test as a screening test for colorectal cancer.
Janssens JF
Acta Gastroenterol Belg; 2005; 68(2):244-6. PubMed ID: 16013643
[TBL] [Abstract][Full Text] [Related]
19. Repeated faecal occult blood testing is associated with decreased advanced colorectal cancer risk: A population-based study.
James PD; Rabeneck L; Yun L; Paszat L; Baxter NN; Govindarajan A; Antonova L; Tinmouth JM
J Med Screen; 2018 Sep; 25(3):141-148. PubMed ID: 28862521
[TBL] [Abstract][Full Text] [Related]
20. Stage of extension and treatment for colorectal cancer after a negative test and among non-responders in mass screening with guaiac faecal occult blood test: a French experience.
Bouvier V; Herbert C; Lefevre H; Launoy G
Eur J Cancer Prev; 2001 Aug; 10(4):323-6. PubMed ID: 11535874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
